NICE yes on final draft guidance for Astellas' Betmiga
This article was originally published in Scrip
Executive Summary
The National Institute for Health and Care Excellence (NICE) in England and Wales has issued final draft guidance recommending Astellas' Betmiga (mirabegron) for reimbursement.